SCHEMBL3740317

SCHEMBL3740317

Cc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1-c1c(N2CCN(CCN(C)C)CC2)c(=O)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.48
KIT P10721 2/20 0.48
RAF1 P04049 2/20 0.48
RET P07949 2/20 0.48
LCK P06239 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAP3K20 Q9NYL2 1/20 0.48
RIPK3 Q9Y572 1/20 0.48
FLT1 P17948 4/20 0.38
ROCK1 Q13464 2/20 0.36
MAPK14 Q16539 1/20 0.34
BRAF P15056 2/20 0.34
FAAH O00519 1/20 0.34
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
BCHE P06276 2/20 0.33
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3738474 0.93 KDR (0.49) KDRKITRAF1RETLCK
SCHEMBL3738048 0.92 KDR (0.50) KDRKITRAF1RETLCK
SCHEMBL3745596 0.92 KDR (0.51) KDRKITRAF1RETLCK
SCHEMBL3738976 0.90 KDR (0.50) KDRKITRAF1RETLCK
SCHEMBL3737502 0.90 KDR (0.52) KDRKITRAF1RETLCK
SCHEMBL3738467 0.89 KDR (0.50) KDRKITRAF1RETLCK
SCHEMBL3731998 0.89 RAF1 (0.51) KDRKITRAF1RETLCK
SCHEMBL13043410 0.85 KDR (0.47) KDRKITRAF1RETLCK
SCHEMBL3737803 0.85 KDR (0.47) KDRKITRAF1RETLCK
SCHEMBL13043435 0.84 KDR (0.57) KDRKITRAF1RETLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060111349-A1 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. 2006-05-25 US claimed
WO-2006034111-A1 (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-03-30 WO claimed
US-7829717-B2 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-7829717-B2 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-7829717-B2 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-20060111349-A1 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111349-A1 (Arylamidoaryl)squaramide compounds KIT, TSSK6, MCTS1 KDR 1120/4885KIT 1/4885RAF1 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.